Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LANCL2 | Q9NS86 | 1/20 | 0.69 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.47 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | ATR | Q13535 | 1/20 | 0.40 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25881549 | 0.94 | LANCL2 (0.66) | LANCL2GPR119SCD5PARP1CYP11B2 | |
| SCHEMBL17706597 | 0.94 | LANCL2 (0.78) | LANCL2GPR119SCD5PARP1MEN1 | |
| SCHEMBL25881623 | 0.94 | LANCL2 (0.64) | LANCL2GPR119SCD5PARP1CYP11B2 | |
| SCHEMBL25881519 | 0.92 | LANCL2 (0.60) | LANCL2GPR119SCD5PARP1CYP11B2 | |
| SCHEMBL29466338 | 0.89 | LANCL2 (0.86) | LANCL2MEN1KMT2AATRHRH4 | |
| SCHEMBL25877375 | 0.89 | LANCL2 (0.86) | LANCL2MEN1KMT2AATRHRH4 | |
| SCHEMBL29484594 | 0.87 | LANCL2 (0.49) | LANCL2GPR119SCD5PARP1CYP11B2 | |
| SCHEMBL25879484 | 0.86 | LANCL2 (0.64) | LANCL2GPR119PARP1PDE10ACHEK2 | |
| SCHEMBL25312093 | 0.85 | LANCL2 (0.79) | LANCL2MEN1KMT2AATRHRH4 | |
| SCHEMBL29466288 | 0.85 | LANCL2 (0.79) | LANCL2MEN1KMT2AATRHRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4215526-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
| EP-4215526-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | Shanghai Pharmaceuticals Holding Co., Ltd. (CN) | 2023-07-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101552-A1 | CARBONYL HETEROCYCLIC COMPOUND AND APPLICATION THEREOF | LANCL2, CBS, LCP2 | LANCL2 1/4885GPR119 485/4885SCD5 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.